Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires looking at a stock holistically.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The consolidation of the Spanish banking sector continues apace, after state-controlled Bankia agreed to take ...

BMN 401 significantly increased plasma PPi at week 52 but failed to achieve significant improvement in RGI-C scores compared with conventional therapy. Topline data were announced from a phase 3 trial ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase ...

ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration ...

This trial is no longer recruiting patients. We hope to add results when they are available. This study is learning more about a new drug called BMN 673, which hasn’t been tested in people before. It ...

The last time I wrote about BioMarin Pharmaceutical (BMRN), it was with respect to a Seeking Alpha article entitled "BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion".